Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07312435 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy.

Study acronym: BOOMERANG
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
University of Oslo
31 trials monitored
See all monitored trials
Dementia
1,978 trials monitored
See 106 trials at risk
A poor nutrition status is a modifiable risk factor for cognitive decline and dementia. In particular, evidence links low status of certain B-vitamins and ω-3 fatty acids (ω-3 FA) with a greater risk of cognitive decline and dementia. Although these dietary components are typically investigated separately, post-hoc analyses of existing clinical trial data and experimental work indicate that B-vitamins and ω-3 FA may exert synergistic beneficial effects on processes related to brain health and cognition. However, this combination has not been tested directly in humans. In the proposed BOOMERANG project, we will study the effects of jointly supplementing with B-vitamins and a highly bioavailable ω-3 FA supplement, Lysoveta, on a robust biomarker of brain atrophy, the neurofilament light chain, in a double-blinded randomized controlled trial (RCT) over 3 months in older adults. We will also examine the secondary effects of the supplement of quality of life and cognitive function.
Trial Details
NCT Number NCT07312435
Lead Sponsor University of Oslo
Collaborators: Maastricht University, University of Dublin, Trinity College, Aker BioMarine, University of Ulster, Heinrich-Heine University, Duesseldorf
Conditions
(from sponsor)		 Dementia, Cognitive Function
Related terms Dementia
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov